Go Pro

Abbott Laboratories (ABT) Financials

Abbott Laboratories logo
$105.58 -1.54 (-1.44%)
Closing price 08/4/2026 03:59 PM Eastern
Extended Trading
$105.63 +0.05 (+0.05%)
As of 08/4/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Abbott Laboratories

Annual Income Statements for Abbott Laboratories

This table shows Abbott Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
4,423 1,400 477 2,368 3,687 4,495 7,071 6,933 5,723 13,402 6,524
Consolidated Net Income / (Loss)
4,423 1,400 477 2,368 3,687 4,495 7,071 6,933 5,723 13,402 6,524
Net Income / (Loss) Continuing Operations
2,606 1,063 353 2,334 3,687 4,471 7,071 6,933 5,723 13,402 6,524
Total Pre-Tax Income
3,183 1,413 2,231 2,873 4,077 4,968 8,211 8,306 6,664 7,013 8,466
Total Operating Income
2,867 3,026 1,564 3,650 4,532 5,357 8,425 8,362 6,478 6,825 8,053
Total Gross Profit
11,658 11,759 14,981 17,872 18,673 19,605 24,538 24,511 22,134 23,244 25,009
Total Revenue
20,405 20,853 27,390 30,578 31,904 34,608 43,075 43,653 40,109 41,950 44,328
Operating Revenue
20,405 20,853 27,390 30,578 31,904 34,608 43,075 43,653 40,109 41,950 44,328
Total Cost of Revenue
8,747 9,094 12,409 12,706 13,231 15,003 18,537 19,142 17,975 18,706 19,319
Operating Cost of Revenue
8,747 9,094 12,409 12,706 13,231 15,003 18,537 19,142 17,975 18,706 19,319
Total Operating Expenses
8,791 8,733 13,417 14,222 14,141 14,248 16,113 16,149 15,656 16,419 16,956
Selling, General & Admin Expense
6,785 6,736 9,182 9,744 11,701 9,696 11,324 11,248 10,949 11,697 12,332
Research & Development Expense
1,405 1,447 2,260 2,300 2,440 2,420 2,742 2,888 2,741 2,844 2,942
Amortization Expense
601 550 1,975 2,178 - 2,132 2,047 2,013 1,966 1,878 1,682
Total Other Income / (Expense), net
316 -1,613 667 -777 -455 -389 -214 -56 186 188 413
Interest Expense
163 431 904 993 733 546 533 558 637 559 493
Interest & Investment Income
105 99 124 105 94 46 43 183 385 344 308
Other Income / (Expense), net
374 -1,281 1,447 111 184 111 276 319 438 403 598
Income Tax Expense
577 350 1,878 539 390 497 1,140 1,373 941 -6,389 1,942
Basic Earnings per Share
$2.94 $0.94 $0.27 $1.34 $2.07 $2.52 $3.97 $3.94 $3.28 $7.67 $3.73
Weighted Average Basic Shares Outstanding
1.50B 1.48B 1.74B 1.76B 1.77B 1.77B 1.78B 1.75B 1.74B 1.74B 1.74B
Diluted Earnings per Share
$2.92 $0.94 $0.27 $1.33 $2.06 $2.50 $3.94 $3.91 $3.26 $7.64 $3.72
Weighted Average Diluted Shares Outstanding
1.51B 1.48B 1.75B 1.77B 1.78B 1.79B 1.79B 1.76B 1.75B 1.75B 1.75B
Weighted Average Basic & Diluted Shares Outstanding
1.50B 1.73B 1.75B 1.77B 1.76B 1.77B 1.76B 1.74B 1.74B 1.73B 1.74B
Cash Dividends to Common per Share
- - - - - - - $1.92 $2.08 $2.24 $2.40

Quarterly Income Statements for Abbott Laboratories

This table shows Abbott Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders
1,594 1,225 1,302 1,646 9,229 1,325 1,779 1,644 1,776 1,077 928
Consolidated Net Income / (Loss)
1,594 1,225 1,302 1,646 9,229 1,325 1,779 1,644 1,776 1,077 928
Net Income / (Loss) Continuing Operations
1,594 1,225 1,302 1,646 9,229 1,325 1,779 1,644 1,776 1,077 928
Total Pre-Tax Income
1,795 1,436 1,607 1,940 2,030 1,778 2,150 2,180 2,358 1,449 1,524
Total Operating Income
1,780 1,386 1,669 1,859 1,911 1,693 2,052 2,057 2,251 1,345 1,693
Total Gross Profit
5,685 5,501 5,774 5,937 6,032 5,890 6,288 6,294 6,537 6,274 7,268
Total Revenue
10,241 9,964 10,377 10,635 10,974 10,358 11,142 11,369 11,459 11,164 12,593
Operating Revenue
10,241 9,964 10,377 10,635 10,974 10,358 11,142 11,369 11,459 11,164 12,593
Total Cost of Revenue
4,556 4,463 4,603 4,698 4,942 4,468 4,854 5,075 4,922 4,890 5,325
Operating Cost of Revenue
4,556 4,463 4,603 4,698 4,942 4,468 4,854 5,075 4,922 4,890 5,325
Total Operating Expenses
3,905 4,115 4,105 4,078 4,121 4,197 4,236 4,237 4,286 4,929 5,575
Selling, General & Admin Expense
2,724 2,959 2,936 2,895 2,907 3,061 3,091 3,051 3,129 3,740 4,025
Research & Development Expense
700 684 698 713 749 716 725 766 735 767 892
Amortization Expense
481 472 471 470 465 420 420 420 422 422 658
Total Other Income / (Expense), net
15 50 -62 81 119 85 98 123 107 104 -169
Interest Expense
159 141 140 142 136 131 121 121 120 174 351
Interest & Investment Income
89 80 82 91 91 82 71 77 78 106 52
Other Income / (Expense), net
85 111 -4.00 132 164 134 148 167 149 172 130
Income Tax Expense
201 211 305 294 -7,199 453 371 536 582 372 596
Basic Earnings per Share
$0.92 $0.70 $0.74 $0.94 $5.29 $0.76 $1.02 $0.94 $1.01 $0.62 $0.53
Weighted Average Basic Shares Outstanding
1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B
Diluted Earnings per Share
$0.91 $0.70 $0.74 $0.94 $5.26 $0.76 $1.01 $0.94 $1.01 $0.61 $0.53
Weighted Average Diluted Shares Outstanding
1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.74B
Weighted Average Basic & Diluted Shares Outstanding
1.74B 1.74B 1.74B 1.73B 1.73B 1.74B 1.74B 1.74B 1.74B 1.74B 1.73B

Annual Cash Flow Statements for Abbott Laboratories

This table details how cash moves in and out of Abbott Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
938 13,619 -9,329 -5,447 16 2,978 2,961 83 -2,986 720 906
Net Cash From Operating Activities
2,966 3,203 5,570 6,300 6,136 7,901 10,533 9,581 7,261 8,558 9,566
Net Cash From Continuing Operating Activities
2,966 3,203 5,570 6,300 6,136 7,901 10,533 9,581 7,261 8,558 9,566
Net Income / (Loss) Continuing Operations
4,423 1,400 477 2,368 3,687 4,495 7,071 6,933 5,723 13,402 6,524
Consolidated Net Income / (Loss)
4,423 1,400 477 2,368 3,687 4,495 7,071 6,933 5,723 13,402 6,524
Depreciation Expense
871 803 1,046 1,100 1,078 1,195 1,491 1,254 1,277 1,340 1,434
Amortization Expense
601 715 2,887 2,210 1,936 2,132 2,047 2,013 1,966 1,878 1,682
Non-Cash Adjustments To Reconcile Net Income
-2,773 1,798 -755 770 766 971 695 900 770 1,155 729
Changes in Operating Assets and Liabilities, net
-156 -1,513 1,915 -148 -1,331 -892 -771 -1,519 -2,475 -9,217 -803
Net Cash From Investing Activities
406 -248 -9,618 -1,356 -1,815 -2,215 -2,008 -1,740 -3,133 -2,338 -2,422
Net Cash From Continuing Investing Activities
406 -248 -9,618 -1,356 -1,815 -2,215 -2,008 -1,740 -3,133 -2,338 -2,422
Purchase of Property, Plant & Equipment
-1,110 -1,121 -1,135 -1,394 -1,638 -2,177 -1,885 -1,777 -2,202 -2,207 -2,171
Acquisitions
-235 -80 -17,183 -54 -170 -42 -187 0.00 -877 0.00 -105
Purchase of Investments
-4,933 -2,823 -210 -131 -103 -83 -173 -185 -159 -169 -167
Divestitures
230 25 6,042 48 48 58 134 48 40 1.00 0.00
Sale and/or Maturity of Investments
6,402 3,709 2,833 73 21 10 77 152 43 28 3.00
Other Investing Activities, net
52 42 35 102 27 19 26 22 22 9.00 18
Net Cash From Financing Activities
-2,236 11,147 -5,281 -10,391 -4,289 -2,779 -5,494 -7,636 -7,091 -5,404 -6,309
Net Cash From Continuing Financing Activities
-2,236 11,147 -5,281 -10,391 -4,289 -2,779 -5,494 -7,636 -7,091 -5,404 -6,309
Repayment of Debt
-1,338 -1,949 -9,684 -12,459 -3,441 -1,342 -252 -706 -2,477 -760 -1,701
Repurchase of Common Equity
-2,237 -522 -117 -238 -718 -403 -2,299 -3,795 -1,227 -1,295 -893
Payment of Dividends
-1,443 -1,539 -1,849 -1,974 -2,270 -2,560 -3,202 -3,309 -3,556 -3,836 -4,116
Issuance of Debt
2,485 14,934 6,742 4,009 1,842 1,281 4.00 7.00 2.00 223 5.00
Other Financing Activities, net
297 223 337 271 298 245 255 167 167 264 396
Effect of Exchange Rate Changes
-198 -483 - - -16 71 -70 -122 - - 71
Cash Interest Paid
166 181 917 845 677 549 544 563 662 604 545
Cash Income Taxes Paid
631 620 570 740 930 970 1,941 1,864 1,475 1,723 1,933

Quarterly Cash Flow Statements for Abbott Laboratories

This table details how cash moves in and out of Abbott Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents
187 -612 703 571 58 -1,084 419 560 1,011 -1,719 -1,699
Net Cash From Operating Activities
3,038 1,025 1,960 2,705 2,868 1,417 2,047 2,787 3,315 1,315 2,488
Net Cash From Continuing Operating Activities
3,038 1,025 1,960 2,705 2,868 1,417 2,047 2,787 3,315 1,315 2,488
Net Income / (Loss) Continuing Operations
1,594 1,225 1,302 1,646 9,229 1,325 1,779 1,644 1,776 1,077 928
Consolidated Net Income / (Loss)
1,594 1,225 1,302 1,646 9,229 1,325 1,779 1,644 1,776 1,077 928
Depreciation Expense
332 333 334 331 342 336 357 371 370 381 402
Amortization Expense
481 472 471 470 465 420 420 420 422 422 658
Non-Cash Adjustments To Reconcile Net Income
240 304 141 117 593 289 142 120 178 317 168
Changes in Operating Assets and Liabilities, net
391 -1,309 -288 141 -7,761 -953 -651 232 569 -882 332
Net Cash From Investing Activities
-824 -425 -453 -594 -866 -470 -582 -457 -913 -20,324 -673
Net Cash From Continuing Investing Activities
-824 -425 -453 -594 -866 -470 -582 -457 -913 -20,324 -673
Purchase of Property, Plant & Equipment
-755 -398 -533 -556 -720 -484 -502 -496 -689 -399 -497
Acquisitions
- - - - - 0.00 - -55 -20 -19,798 -164
Purchase of Investments
-114 -28 77 -40 -178 8.00 - 90 -213 -161 -26
Other Investing Activities, net
2.00 1.00 2.00 2.00 4.00 6.00 2.00 4.00 6.00 34 14
Net Cash From Financing Activities
-2,052 -1,176 -791 -1,576 -1,861 -2,055 -1,097 -1,760 -1,397 17,313 -3,518
Net Cash From Continuing Financing Activities
-2,052 -1,176 -791 -1,576 -1,861 -2,055 -1,097 -1,760 -1,397 17,313 -3,518
Repayment of Debt
-940 -127 -61 42 -614 -1,037 -99 -493 -72 -1,385 -1,341
Repurchase of Common Equity
-259 -226 -3.00 -751 -315 -280 -6.00 -305 -302 -180 -1,045
Payment of Dividends
-888 -957 -961 -960 -958 -1,026 -1,029 -1,031 -1,030 -1,098 -1,102
Issuance of Debt
1.00 0.00 - 1.00 1.00 1.00 2.00 - 2.00 19,860 -33
Other Financing Activities, net
34 134 13 92 25 287 35 69 5.00 116 3.00
Effect of Exchange Rate Changes
25 - -13 36 -83 24 51 -10 6.00 -23 4.00

Annual Balance Sheets for Abbott Laboratories

This table presents Abbott Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
41,247 52,666 76,250 67,173 67,887 72,548 75,196 74,438 73,214 81,414 86,713
Total Current Assets
14,155 26,776 20,147 14,632 15,667 20,441 24,239 25,224 22,670 23,656 25,996
Cash & Equivalents
5,001 18,620 9,407 3,844 3,860 6,838 9,799 9,882 6,896 7,616 8,522
Short-Term Investments
1,124 155 203 242 280 310 450 288 383 351 417
Accounts Receivable
3,418 3,248 5,249 5,182 5,425 6,414 6,487 6,218 6,565 6,925 7,929
Inventories, net
2,599 2,434 3,601 3,796 4,316 5,012 5,157 6,173 6,570 6,194 6,488
Prepaid Expenses
- - 1,667 1,568 1,786 1,867 2,346 2,663 2,256 2,570 2,640
Plant, Property, & Equipment, net
5,730 5,705 7,607 7,563 8,038 9,029 8,959 9,162 10,154 10,658 11,816
Plant, Property & Equipment, gross
12,383 12,366 15,265 15,706 16,799 18,793 19,364 20,212 21,933 22,740 25,222
Accumulated Depreciation
6,653 6,661 7,658 8,143 8,761 9,764 10,405 11,050 11,779 12,082 13,406
Total Noncurrent Assets
21,362 20,185 48,496 44,978 44,182 43,078 41,998 40,052 40,390 47,100 48,901
Long-Term Investments
4,041 2,947 883 897 883 821 816 766 799 886 918
Goodwill
9,638 7,683 24,020 23,254 23,195 23,744 23,231 22,799 23,679 23,108 24,035
Intangible Assets
5,562 4,539 21,473 18,942 17,025 14,784 12,739 10,454 8,815 6,647 5,526
Noncurrent Deferred & Refundable Income Taxes
2,119 2,263 1,944 1,885 3,079 3,729 5,212 6,033 7,097 16,459 18,422
Total Liabilities & Shareholders' Equity
41,247 52,666 76,250 67,173 67,887 72,548 75,196 74,438 73,214 81,414 86,713
Total Liabilities
19,921 31,949 45,152 36,451 36,586 39,545 39,172 37,533 34,387 33,513 33,942
Total Current Liabilities
9,186 6,660 8,912 9,012 10,863 11,907 13,105 15,489 13,841 14,157 16,496
Short-Term Debt
3,130 1,325 714 207 1,478 220 754 2,251 1,080 1,500 3,033
Accounts Payable
1,081 1,178 2,402 2,975 3,252 3,946 4,408 4,607 4,295 4,195 4,240
Accrued Expenses
3,043 2,581 3,811 3,780 4,035 5,165 5,181 5,845 5,422 5,143 5,812
Dividends Payable
383 391 489 563 635 798 831 887 955 1,024 1,097
Current Deferred & Payable Income Tax Liabilities
430 188 309 305 226 362 306 343 492 594 569
Current Employee Benefit Liabilities
746 752 1,187 1,182 1,237 1,416 1,625 1,556 1,597 1,701 1,745
Total Noncurrent Liabilities
10,735 25,289 36,240 27,439 25,723 27,638 26,067 22,044 20,546 19,356 17,446
Long-Term Debt
5,871 20,681 27,210 19,359 16,661 18,527 17,296 14,522 13,599 12,625 9,896
Noncurrent Deferred & Payable Income Tax Liabilities
- - 9,030 8,080 - - - - - - 7,550
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
21,326 20,717 31,098 30,722 31,301 33,003 36,024 36,905 38,827 47,901 52,771
Total Preferred & Common Equity
21,211 20,538 30,897 30,524 31,088 32,784 35,802 36,686 38,603 47,664 52,130
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
21,211 20,538 30,897 30,524 31,088 32,784 35,802 36,686 38,603 47,664 52,130
Common Stock
12,734 13,027 23,206 23,512 23,853 24,145 24,470 24,709 24,869 25,153 25,527
Retained Earnings
25,757 25,565 23,978 24,560 25,847 27,627 31,528 35,257 37,554 47,261 49,781
Accumulated Other Comprehensive Income / (Loss)
-6,658 -7,263 -6,062 -7,586 -8,465 -8,946 -8,374 -8,051 -7,839 -7,906 -6,001
Other Equity Adjustments
- - - -9,962 - - -11,822 -15,229 -15,981 - -17,177
Noncontrolling Interest
115 179 201 198 213 219 222 219 224 237 641

Quarterly Balance Sheets for Abbott Laboratories

This table presents Abbott Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets
72,090 73,214 72,467 73,017 74,356 81,414 81,448 83,999 84,181 110,429 109,215
Total Current Assets
22,664 22,670 22,376 23,119 23,802 23,656 23,153 24,468 24,839 25,508 24,517
Cash & Equivalents
6,709 6,896 6,284 6,987 7,558 7,616 6,532 6,951 7,511 6,803 5,104
Short-Term Investments
338 383 367 232 230 351 312 331 222 492 499
Accounts Receivable
6,499 6,565 6,605 6,854 7,051 6,925 7,327 7,972 8,138 8,210 8,599
Inventories, net
6,650 6,570 6,827 6,814 6,813 6,194 6,639 6,954 6,708 6,989 7,315
Prepaid Expenses
2,468 2,256 2,293 2,232 2,150 2,570 2,343 2,260 2,260 3,014 3,000
Plant, Property, & Equipment, net
9,552 10,154 10,107 10,233 10,621 10,658 10,932 11,395 11,504 12,377 12,812
Plant, Property & Equipment, gross
21,111 21,933 22,055 22,061 22,857 22,740 23,418 24,472 24,816 25,737 26,469
Accumulated Depreciation
11,559 11,779 11,948 11,828 12,236 12,082 12,486 13,077 13,312 13,360 13,657
Total Noncurrent Assets
39,874 40,390 39,984 39,665 39,933 47,100 47,363 48,136 47,838 72,544 71,886
Long-Term Investments
788 799 818 877 912 886 907 958 951 1,090 1,111
Goodwill
23,277 23,679 23,383 23,308 23,658 23,108 23,359 23,952 23,971 35,221 35,244
Intangible Assets
9,282 8,815 8,296 7,827 7,352 6,647 6,261 5,920 5,598 17,875 17,211
Noncurrent Deferred & Refundable Income Taxes
6,527 7,097 7,487 7,653 8,011 16,459 16,836 17,306 17,318 18,358 18,320
Total Liabilities & Shareholders' Equity
72,090 73,214 72,467 73,017 74,356 81,414 81,448 83,999 84,181 110,429 109,215
Total Liabilities
34,396 34,387 33,424 33,457 34,328 33,513 32,384 33,170 32,917 57,728 57,453
Total Current Liabilities
13,042 13,841 14,021 13,760 14,902 14,157 13,004 13,439 14,582 18,377 17,814
Short-Term Debt
1,051 1,080 2,010 1,615 2,154 1,500 506 507 1,345 4,409 3,005
Accounts Payable
3,961 4,295 4,178 4,125 4,034 4,195 4,214 4,306 4,123 4,679 4,794
Accrued Expenses
5,347 5,422 5,220 5,071 5,427 5,143 5,600 5,656 5,880 6,379 6,892
Dividends Payable
886 955 959 959 956 1,024 1,032 1,030 1,030 1,100 1,093
Current Deferred & Payable Income Tax Liabilities
318 492 562 601 713 594 485 390 469 598 411
Current Employee Benefit Liabilities
1,479 1,597 1,092 1,389 1,618 1,701 1,167 1,550 1,735 1,212 1,619
Total Noncurrent Liabilities
21,354 20,546 19,403 19,697 19,426 19,356 19,380 19,731 18,335 39,351 39,639
Long-Term Debt
14,477 13,599 12,576 13,139 12,825 12,625 12,736 12,930 11,596 29,638 29,603
Noncurrent Deferred & Payable Income Tax Liabilities
6,877 - 6,827 6,558 6,601 - 6,644 6,801 6,739 9,713 10,036
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
37,694 38,827 39,043 39,560 40,028 47,901 49,064 50,829 51,264 52,701 51,762
Total Preferred & Common Equity
37,481 38,603 38,810 39,318 39,796 47,664 48,811 50,565 50,954 52,061 51,110
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
37,481 38,603 38,810 39,318 39,796 47,664 48,811 50,565 50,954 52,061 51,110
Common Stock
24,727 24,869 24,726 24,858 25,020 25,153 25,125 25,284 25,412 25,352 25,495
Retained Earnings
36,920 37,554 38,011 38,354 39,056 47,261 47,715 48,467 49,103 49,956 49,794
Treasury Stock
-15,686 - - -15,759 -16,476 -16,844 -16,612 - -16,877 -16,935 -17,967
Accumulated Other Comprehensive Income / (Loss)
-8,480 -7,839 -8,166 -8,135 -7,804 -7,906 -7,417 -6,576 -6,684 -6,312 -6,212
Noncontrolling Interest
213 224 233 242 232 237 253 264 310 640 652

Annual Metrics And Ratios for Abbott Laboratories

This table displays calculated financial ratios and metrics derived from Abbott Laboratories' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.78% 2.20% 31.35% 11.64% 4.34% 8.48% 24.47% 1.34% -8.12% 4.59% 5.67%
EBITDA Growth
13.38% -30.77% 112.81% 1.83% 9.32% 13.78% 39.16% -2.38% -14.97% 2.83% 12.65%
EBIT Growth
24.22% -46.16% 72.55% 24.91% 25.39% 15.95% 59.13% -0.23% -20.33% 4.51% 19.69%
NOPAT Growth
32.14% -3.02% -89.13% 1,098.25% 38.22% 17.63% 50.49% -3.80% -20.29% 134.44% -52.42%
Net Income Growth
93.65% -68.35% -65.93% 396.44% 55.70% 21.91% 57.31% -1.95% -17.45% 134.18% -51.32%
EPS Growth
95.97% -67.81% -71.28% 392.59% 54.89% 21.36% 57.60% -0.76% -16.62% 134.36% -51.31%
Operating Cash Flow Growth
-19.29% 7.99% 73.90% 13.11% -2.60% 28.76% 33.31% -9.04% -24.21% 17.86% 11.78%
Free Cash Flow Firm Growth
84.66% 0.33% -747.37% 119.64% -16.97% 7.72% 51.00% -10.05% -60.93% 86.12% -33.77%
Invested Capital Growth
-9.93% -11.44% 164.91% -6.05% -1.78% -1.05% -1.66% -0.48% 6.31% 16.85% 5.06%
Revenue Q/Q Growth
-0.70% 0.70% 8.98% 0.58% 1.75% 7.41% 1.81% -3.06% 0.38% 1.78% 1.11%
EBITDA Q/Q Growth
-0.59% 9.50% 3.15% 3.63% 3.34% 15.54% -0.42% -8.69% 5.01% 1.99% 2.71%
EBIT Q/Q Growth
0.03% 10.44% -6.78% 11.90% 5.76% 24.41% -0.78% -10.89% 7.44% 2.99% 3.90%
NOPAT Q/Q Growth
1.16% 2.76% -81.43% 190.04% 9.32% 26.98% -2.24% -12.68% 11.13% 129.00% -53.15%
Net Income Q/Q Growth
-3.03% 2.26% -77.32% 167.27% 12.00% 32.91% -2.39% -12.12% 10.87% 132.39% -53.32%
EPS Q/Q Growth
-4.26% 3.30% -78.91% 171.43% 11.96% 32.28% -2.23% -11.74% 10.88% 132.22% -53.33%
Operating Cash Flow Q/Q Growth
-12.14% 11.95% 9.22% 2.02% 11.87% 21.20% -6.49% -7.18% 10.87% -1.95% 4.90%
Free Cash Flow Firm Q/Q Growth
-82.50% 126.77% -30.39% 551.28% 32.18% 6.70% -14.56% -18.97% 138.07% 11.12% -12.54%
Invested Capital Q/Q Growth
0.00% -6.03% 10.80% -1.14% -2.96% -1.51% 1.18% 2.78% 0.24% 14.67% 0.69%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
57.13% 56.39% 54.70% 58.45% 58.53% 56.65% 56.97% 56.15% 55.18% 55.41% 56.42%
EBITDA Margin
23.10% 15.65% 25.35% 23.12% 24.23% 25.41% 28.41% 27.37% 25.33% 24.90% 26.55%
Operating Margin
14.05% 14.51% 5.71% 11.94% 14.21% 15.48% 19.56% 19.16% 16.15% 16.27% 18.17%
EBIT Margin
15.88% 8.37% 10.99% 12.30% 14.78% 15.80% 20.20% 19.89% 17.24% 17.23% 19.52%
Profit (Net Income) Margin
21.68% 6.71% 1.74% 7.74% 11.56% 12.99% 16.42% 15.88% 14.27% 31.95% 14.72%
Tax Burden Percent
138.96% 99.08% 21.38% 82.42% 90.43% 90.48% 86.12% 83.47% 85.88% 191.10% 77.06%
Interest Burden Percent
98.21% 80.97% 74.10% 76.39% 86.45% 90.86% 94.37% 95.68% 96.36% 97.03% 97.86%
Effective Tax Rate
18.13% 24.77% 84.18% 18.76% 9.57% 10.00% 13.88% 16.53% 14.12% -91.10% 22.94%
Return on Invested Capital (ROIC)
10.69% 11.60% 0.74% 6.26% 9.02% 10.76% 16.41% 15.96% 12.36% 25.94% 11.17%
ROIC Less NNEP Spread (ROIC-NNEP)
448.14% 74.14% 3.71% 2.63% 6.17% 8.18% 14.51% 15.32% 14.60% 31.12% 17.25%
Return on Net Nonoperating Assets (RNNOA)
9.90% -4.94% 1.11% 1.40% 2.87% 3.22% 4.08% 3.05% 2.75% 4.97% 1.79%
Return on Equity (ROE)
20.59% 6.66% 1.84% 7.66% 11.89% 13.98% 20.49% 19.01% 15.11% 30.91% 12.96%
Cash Return on Invested Capital (CROIC)
21.14% 23.73% -89.65% 12.50% 10.81% 11.81% 18.08% 16.44% 6.24% 10.40% 6.23%
Operating Return on Assets (OROA)
7.86% 3.72% 4.67% 5.24% 6.98% 7.79% 11.78% 11.60% 9.37% 9.35% 10.29%
Return on Assets (ROA)
10.73% 2.98% 0.74% 3.30% 5.46% 6.40% 9.57% 9.27% 7.75% 17.33% 7.76%
Return on Common Equity (ROCE)
20.48% 6.61% 1.83% 7.61% 11.81% 13.89% 20.36% 18.90% 15.03% 30.74% 12.85%
Return on Equity Simple (ROE_SIMPLE)
20.85% 6.82% 1.54% 7.76% 11.86% 13.71% 19.75% 18.90% 14.83% 28.12% 0.00%
Net Operating Profit after Tax (NOPAT)
2,347 2,276 247 2,965 4,098 4,821 7,255 6,980 5,563 13,043 6,206
NOPAT Margin
11.50% 10.92% 0.90% 9.70% 12.85% 13.93% 16.84% 15.99% 13.87% 31.09% 14.00%
Net Nonoperating Expense Percent (NNEP)
-437.45% -62.54% -2.97% 3.63% 2.85% 2.58% 1.90% 0.64% -2.24% -5.19% -6.08%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 13.00% 10.40% 21.03% 9.45%
Cost of Revenue to Revenue
42.87% 43.61% 45.30% 41.55% 41.47% 43.35% 43.03% 43.85% 44.82% 44.59% 43.58%
SG&A Expenses to Revenue
33.25% 32.30% 33.52% 31.87% 36.68% 28.02% 26.29% 25.77% 27.30% 27.88% 27.82%
R&D to Revenue
6.89% 6.94% 8.25% 7.52% 7.65% 6.99% 6.37% 6.62% 6.83% 6.78% 6.64%
Operating Expenses to Revenue
43.08% 41.88% 48.99% 46.51% 44.32% 41.17% 37.41% 36.99% 39.03% 39.14% 38.25%
Earnings before Interest and Taxes (EBIT)
3,241 1,745 3,011 3,761 4,716 5,468 8,701 8,681 6,916 7,228 8,651
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
4,713 3,263 6,944 7,071 7,730 8,795 12,239 11,948 10,159 10,446 11,767
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.68 2.39 2.86 3.77 4.55 5.54 6.60 4.99 4.83 4.09 4.16
Price to Tangible Book Value (P/TBV)
9.44 5.91 0.00 0.00 0.00 0.00 0.00 53.32 30.51 10.90 9.60
Price to Revenue (P/Rev)
2.78 2.36 3.23 3.76 4.43 5.24 5.49 4.19 4.65 4.65 4.89
Price to Earnings (P/E)
12.83 35.12 185.24 48.59 38.36 40.38 33.43 26.40 32.57 14.56 33.23
Dividend Yield
2.52% 3.11% 2.09% 1.71% 1.60% 1.41% 1.35% 1.79% 1.90% 1.96% 1.89%
Earnings Yield
7.79% 2.85% 0.54% 2.06% 2.61% 2.48% 2.99% 3.79% 3.07% 6.87% 3.01%
Enterprise Value to Invested Capital (EV/IC)
2.68 2.69 2.17 2.83 3.44 4.32 5.56 4.33 4.17 3.70 3.87
Enterprise Value to Revenue (EV/Rev)
2.73 2.38 3.87 4.25 4.85 5.56 5.65 4.33 4.82 4.78 4.97
Enterprise Value to EBITDA (EV/EBITDA)
11.82 15.21 15.26 18.36 20.02 21.89 19.90 15.83 19.02 19.21 18.74
Enterprise Value to EBIT (EV/EBIT)
17.19 28.44 35.20 34.53 32.82 35.21 27.99 21.78 27.93 27.76 25.49
Enterprise Value to NOPAT (EV/NOPAT)
23.73 21.80 428.31 43.79 37.76 39.93 33.57 27.09 34.73 15.39 35.53
Enterprise Value to Operating Cash Flow (EV/OCF)
18.78 15.49 19.03 20.61 25.22 24.36 23.13 19.74 26.61 23.45 23.05
Enterprise Value to Free Cash Flow (EV/FCFF)
12.00 10.66 0.00 21.94 31.49 36.36 30.47 26.30 68.77 38.38 63.67
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.42 1.06 0.90 0.64 0.58 0.57 0.50 0.45 0.38 0.29 0.25
Long-Term Debt to Equity
0.28 1.00 0.88 0.63 0.53 0.56 0.48 0.39 0.35 0.26 0.19
Financial Leverage
0.02 -0.07 0.30 0.53 0.47 0.39 0.28 0.20 0.19 0.16 0.10
Leverage Ratio
1.92 2.23 2.49 2.32 2.18 2.18 2.14 2.05 1.95 1.78 1.67
Compound Leverage Factor
1.88 1.81 1.84 1.77 1.88 1.98 2.02 1.96 1.88 1.73 1.63
Debt to Total Capital
29.68% 51.51% 47.31% 38.91% 36.69% 36.23% 33.38% 31.25% 27.43% 22.77% 19.68%
Short-Term Debt to Total Capital
10.32% 3.10% 1.21% 0.41% 2.99% 0.43% 1.39% 4.19% 2.02% 2.42% 4.62%
Long-Term Debt to Total Capital
19.36% 48.41% 46.10% 38.50% 33.70% 35.80% 31.99% 27.05% 25.42% 20.35% 15.06%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.38% 0.42% 0.34% 0.39% 0.43% 0.42% 0.41% 0.41% 0.42% 0.38% 0.98%
Common Equity to Total Capital
69.94% 48.07% 52.35% 60.70% 62.88% 63.35% 66.21% 68.34% 72.15% 76.85% 79.35%
Debt to EBITDA
1.91 6.74 4.02 2.77 2.35 2.13 1.47 1.40 1.44 1.35 1.10
Net Debt to EBITDA
-0.25 0.09 2.51 2.06 1.70 1.23 0.57 0.49 0.65 0.50 0.26
Long-Term Debt to EBITDA
1.25 6.34 3.92 2.74 2.16 2.11 1.41 1.22 1.34 1.21 0.84
Debt to NOPAT
3.83 9.67 112.84 6.60 4.43 3.89 2.49 2.40 2.64 1.08 2.08
Net Debt to NOPAT
-0.50 0.12 70.44 4.92 3.20 2.24 0.96 0.84 1.19 0.40 0.50
Long-Term Debt to NOPAT
2.50 9.08 109.96 6.53 4.07 3.84 2.38 2.08 2.44 0.97 1.59
Altman Z-Score
3.48 2.57 2.28 3.15 3.64 4.15 5.34 4.72 4.97 5.26 5.61
Noncontrolling Interest Sharing Ratio
0.53% 0.70% 0.73% 0.65% 0.66% 0.67% 0.64% 0.60% 0.59% 0.53% 0.87%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.54 4.02 2.26 1.62 1.44 1.72 1.85 1.63 1.64 1.67 1.58
Quick Ratio
1.04 3.31 1.67 1.03 0.88 1.14 1.28 1.06 1.00 1.05 1.02
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
4,641 4,656 -30,145 5,919 4,914 5,294 7,994 7,191 2,809 5,229 3,463
Operating Cash Flow to CapEx
267.21% 285.73% 490.75% 451.94% 374.60% 362.93% 558.78% 539.17% 329.75% 387.77% 440.63%
Free Cash Flow to Firm to Interest Expense
28.47 10.80 -33.35 5.96 6.70 9.70 15.00 12.89 4.41 9.35 7.02
Operating Cash Flow to Interest Expense
18.20 7.43 6.16 6.34 8.37 14.47 19.76 17.17 11.40 15.31 19.40
Operating Cash Flow Less CapEx to Interest Expense
11.39 4.83 4.91 4.94 6.14 10.48 16.23 13.99 7.94 11.36 15.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.49 0.44 0.42 0.43 0.47 0.49 0.58 0.58 0.54 0.54 0.53
Accounts Receivable Turnover
5.83 6.26 6.45 5.86 6.02 5.85 6.68 6.87 6.28 6.22 5.97
Inventory Turnover
3.34 3.61 4.11 3.44 3.26 3.22 3.65 3.38 2.82 2.93 3.05
Fixed Asset Turnover
3.50 3.65 4.12 4.03 4.09 4.06 4.79 4.82 4.15 4.03 3.94
Accounts Payable Turnover
8.16 8.05 6.93 4.73 4.25 4.17 4.44 4.25 4.04 4.41 4.58
Days Sales Outstanding (DSO)
62.64 58.34 56.62 62.26 60.68 62.43 54.66 53.12 58.16 58.69 61.15
Days Inventory Outstanding (DIO)
109.37 101.00 88.76 106.25 111.89 113.47 100.12 108.02 129.38 124.53 119.80
Days Payable Outstanding (DPO)
44.75 45.33 52.65 77.23 85.89 87.56 82.25 85.95 90.38 82.83 79.68
Cash Conversion Cycle (CCC)
127.26 114.01 92.72 91.27 86.68 88.34 72.53 75.19 97.16 100.39 101.27
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
20,810 18,430 48,822 45,868 45,052 44,579 43,840 43,629 46,383 54,197 56,940
Invested Capital Turnover
0.93 1.06 0.81 0.65 0.70 0.77 0.97 1.00 0.89 0.83 0.80
Increase / (Decrease) in Invested Capital
-2,294 -2,380 30,392 -2,954 -816 -473 -739 -211 2,754 7,814 2,743
Enterprise Value (EV)
55,710 49,625 105,991 129,850 154,775 192,505 243,582 189,096 193,196 200,669 220,478
Market Capitalization
56,760 49,162 88,359 115,069 141,446 181,508 236,375 183,040 186,371 195,160 216,765
Book Value per Share
$14.18 $13.95 $17.75 $17.38 $17.58 $18.50 $20.25 $21.04 $22.24 $27.48 $29.98
Tangible Book Value per Share
$4.02 $5.65 ($8.39) ($6.65) ($5.16) ($3.24) ($0.10) $1.97 $3.52 $10.33 $12.98
Total Capital
30,327 42,723 59,022 50,288 49,440 51,750 54,074 53,678 53,506 62,026 65,700
Total Debt
9,001 22,006 27,924 19,566 18,139 18,747 18,050 16,773 14,679 14,125 12,929
Total Long-Term Debt
5,871 20,681 27,210 19,359 16,661 18,527 17,296 14,522 13,599 12,625 9,896
Net Debt
-1,165 284 17,431 14,583 13,116 10,778 6,985 5,837 6,601 5,272 3,072
Capital Expenditures (CapEx)
1,110 1,121 1,135 1,394 1,638 2,177 1,885 1,777 2,202 2,207 2,171
Debt-free, Cash-free Net Working Capital (DFCFNWC)
1,974 2,666 2,339 1,741 2,142 1,606 1,639 1,816 2,630 3,032 3,594
Debt-free Net Working Capital (DFNWC)
8,099 21,441 11,949 5,827 6,282 8,754 11,888 11,986 9,909 10,999 12,533
Net Working Capital (NWC)
4,969 20,116 11,235 5,620 4,804 8,534 11,134 9,735 8,829 9,499 9,500
Net Nonoperating Expense (NNE)
-2,076 876 -230 597 411 326 184 47 -160 -359 -318
Net Nonoperating Obligations (NNO)
-516 -2,287 17,724 15,146 13,751 11,576 7,816 6,724 7,556 6,296 4,169
Total Depreciation and Amortization (D&A)
1,472 1,518 3,933 3,310 3,014 3,327 3,538 3,267 3,243 3,218 3,116
Debt-free, Cash-free Net Working Capital to Revenue
9.67% 12.78% 8.54% 5.69% 6.71% 4.64% 3.81% 4.16% 6.56% 7.23% 8.11%
Debt-free Net Working Capital to Revenue
39.69% 102.82% 43.63% 19.06% 19.69% 25.29% 27.60% 27.46% 24.71% 26.22% 28.27%
Net Working Capital to Revenue
24.35% 96.47% 41.02% 18.38% 15.06% 24.66% 25.85% 22.30% 22.01% 22.64% 21.43%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$2.94 $0.94 $0.27 $1.34 $2.07 $2.52 $3.97 $3.94 $3.28 $7.67 $3.73
Adjusted Weighted Average Basic Shares Outstanding
1.50B 1.48B 1.74B 1.76B 1.77B 1.77B 1.78B 1.75B 1.74B 1.74B 1.74B
Adjusted Diluted Earnings per Share
$2.92 $0.94 $0.27 $1.33 $2.06 $2.50 $3.94 $3.91 $3.26 $7.64 $3.72
Adjusted Weighted Average Diluted Shares Outstanding
1.51B 1.48B 1.75B 1.77B 1.78B 1.79B 1.79B 1.76B 1.75B 1.75B 1.75B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $2.07 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.47B 1.73B 1.75B 1.76B 1.76B 1.77B 1.76B 1.74B 1.74B 1.73B 1.74B
Normalized Net Operating Profit after Tax (NOPAT)
2,347 2,276 1,095 2,965 4,098 4,821 7,255 6,980 5,563 4,778 6,206
Normalized NOPAT Margin
11.50% 10.92% 4.00% 9.70% 12.85% 13.93% 16.84% 15.99% 13.87% 11.39% 14.00%
Pre Tax Income Margin
15.60% 6.78% 8.15% 9.40% 12.78% 14.36% 19.06% 19.03% 16.61% 16.72% 19.10%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
19.88 4.05 3.33 3.79 6.43 10.01 16.32 15.56 10.86 12.93 17.55
NOPAT to Interest Expense
14.40 5.28 0.27 2.99 5.59 8.83 13.61 12.51 8.73 23.33 12.59
EBIT Less CapEx to Interest Expense
13.07 1.45 2.08 2.38 4.20 6.03 12.79 12.37 7.40 8.98 13.14
NOPAT Less CapEx to Interest Expense
7.59 2.68 -0.98 1.58 3.36 4.84 10.08 9.32 5.28 19.38 8.18
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
32.62% 109.93% 387.63% 83.36% 61.57% 56.95% 45.28% 47.73% 62.14% 28.62% 63.09%
Augmented Payout Ratio
83.20% 147.21% 412.16% 93.41% 81.04% 65.92% 77.80% 102.47% 83.58% 38.29% 76.78%

Quarterly Metrics And Ratios for Abbott Laboratories

This table displays calculated financial ratios and metrics derived from Abbott Laboratories' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding
- - - - - - - - - 1,741,812,429.00 1,730,383,296.00
DEI Adjusted Shares Outstanding
- - - - - - - - - 1,741,812,429.00 1,730,383,296.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - 0.62 0.54
Growth Metrics
- - - - - - - - - - -
Revenue Growth
1.49% 2.23% 4.00% 4.85% 7.16% 3.95% 7.37% 6.90% 4.42% 7.78% 13.02%
EBITDA Growth
22.12% -4.88% -1.08% 8.89% 7.62% 12.21% 20.53% 7.99% 10.76% -10.18% -3.16%
EBIT Growth
34.56% -7.25% -1.89% 14.43% 11.26% 22.04% 32.13% 11.70% 15.66% -16.97% -17.14%
NOPAT Growth
54.90% -7.14% 4.34% 11.44% 449.64% 6.71% 25.56% -1.65% -80.49% -20.76% -39.28%
Net Income Growth
54.31% -7.06% -5.31% 14.62% 478.98% 8.16% 36.64% -0.12% -80.76% -18.72% -47.84%
EPS Growth
54.24% -6.67% -5.13% 14.63% 478.02% 8.57% 36.49% 0.00% -80.80% -19.74% -47.52%
Operating Cash Flow Growth
30.61% -10.32% 62.93% 44.11% -5.60% 38.24% 4.44% 3.03% 15.59% -7.20% 21.54%
Free Cash Flow Firm Growth
-195.28% -203.50% 158.56% 124.36% 174.49% -488.44% -2,390.13% -1,417.40% -219.86% -217.45% -152.56%
Invested Capital Growth
6.31% 5.38% 2.15% 2.14% 16.85% 17.97% 20.94% 19.65% 5.06% 42.95% 38.02%
Revenue Q/Q Growth
0.97% -2.70% 4.14% 2.49% 3.19% -5.61% 7.57% 2.04% 0.79% -2.57% 12.80%
EBITDA Q/Q Growth
4.45% -14.04% 7.30% 13.04% 3.22% -10.37% 15.25% 1.28% 5.87% -27.32% 24.27%
EBIT Q/Q Growth
7.18% -19.73% 11.22% 19.58% 4.22% -11.95% 20.42% 1.09% 7.91% -36.79% 20.17%
NOPAT Q/Q Growth
11.68% -25.20% 14.37% 16.64% 450.82% -85.48% 34.58% -8.64% 9.29% -41.03% 3.12%
Net Income Q/Q Growth
11.00% -23.15% 6.29% 26.42% 460.69% -85.64% 34.26% -7.59% 8.03% -39.36% -13.83%
EPS Q/Q Growth
10.98% -23.08% 5.71% 27.03% 459.57% -85.55% 32.89% -6.93% 7.45% -39.60% -13.11%
Operating Cash Flow Q/Q Growth
61.85% -66.26% 91.22% 38.01% 6.03% -50.59% 44.46% 36.15% 18.95% -60.33% 89.20%
Free Cash Flow Firm Q/Q Growth
51.33% -4.38% 129.17% 64.40% 48.82% -924.53% -13.53% 5.43% 86.46% -2,083.71% 9.68%
Invested Capital Q/Q Growth
0.24% 1.59% 0.12% 0.18% 14.67% 2.56% 2.64% -0.89% 0.69% 39.56% -0.90%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
55.51% 55.21% 55.64% 55.83% 54.97% 56.86% 56.44% 55.36% 57.05% 56.20% 57.71%
EBITDA Margin
26.15% 23.10% 23.80% 26.25% 26.26% 24.94% 26.72% 26.52% 27.86% 20.78% 22.89%
Operating Margin
17.38% 13.91% 16.08% 17.48% 17.41% 16.34% 18.42% 18.09% 19.64% 12.05% 13.44%
EBIT Margin
18.21% 15.02% 16.05% 18.72% 18.91% 17.64% 19.75% 19.56% 20.94% 13.59% 14.48%
Profit (Net Income) Margin
15.56% 12.29% 12.55% 15.48% 84.10% 12.79% 15.97% 14.46% 15.50% 9.65% 7.37%
Tax Burden Percent
88.80% 85.31% 81.02% 84.85% 454.63% 74.52% 82.74% 75.41% 75.32% 74.33% 60.89%
Interest Burden Percent
96.25% 95.93% 96.52% 97.44% 97.83% 97.32% 97.73% 98.02% 98.25% 95.52% 83.60%
Effective Tax Rate
11.20% 14.69% 18.98% 15.15% -354.63% 25.48% 17.26% 24.59% 24.68% 25.67% 39.11%
Return on Invested Capital (ROIC)
13.76% 10.42% 11.37% 13.07% 66.04% 10.04% 12.61% 11.52% 11.80% 5.99% 5.62%
ROIC Less NNEP Spread (ROIC-NNEP)
13.94% 10.97% 10.76% 13.94% 73.85% 10.91% 13.78% 13.01% 13.34% 6.45% 5.00%
Return on Net Nonoperating Assets (RNNOA)
2.63% 2.24% 2.29% 2.84% 11.80% 1.81% 2.11% 1.78% 1.39% 2.11% 1.62%
Return on Equity (ROE)
16.38% 12.66% 13.66% 15.91% 77.83% 11.85% 14.72% 13.31% 13.19% 8.09% 7.23%
Cash Return on Invested Capital (CROIC)
6.24% 6.68% 9.72% 10.06% 10.40% 9.01% 6.57% 7.63% 6.23% -26.56% -24.13%
Operating Return on Assets (OROA)
9.89% 8.28% 8.93% 10.54% 10.26% 9.71% 10.84% 10.82% 11.04% 6.39% 6.98%
Return on Assets (ROA)
8.46% 6.78% 6.98% 8.71% 45.63% 7.04% 8.77% 8.00% 8.17% 4.54% 3.55%
Return on Common Equity (ROCE)
16.29% 12.58% 13.58% 15.82% 77.42% 11.79% 14.63% 13.23% 13.07% 8.02% 7.17%
Return on Equity Simple (ROE_SIMPLE)
0.00% 14.51% 14.13% 14.49% 0.00% 27.66% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
1,581 1,182 1,352 1,577 8,688 1,262 1,698 1,551 1,695 1,000 1,031
NOPAT Margin
15.43% 11.87% 13.03% 14.83% 79.17% 12.18% 15.24% 13.64% 14.80% 8.95% 8.19%
Net Nonoperating Expense Percent (NNEP)
-0.19% -0.55% 0.61% -0.87% -7.81% -0.87% -1.17% -1.48% -1.54% -0.46% 0.62%
Return On Investment Capital (ROIC_SIMPLE)
2.95% - - - 14.01% 2.02% 2.64% 2.42% 2.58% 1.15% 1.22%
Cost of Revenue to Revenue
44.49% 44.79% 44.36% 44.17% 45.03% 43.14% 43.56% 44.64% 42.95% 43.80% 42.29%
SG&A Expenses to Revenue
26.60% 29.70% 28.29% 27.22% 26.49% 29.55% 27.74% 26.84% 27.31% 33.50% 31.96%
R&D to Revenue
6.84% 6.86% 6.73% 6.70% 6.83% 6.91% 6.51% 6.74% 6.41% 6.87% 7.08%
Operating Expenses to Revenue
38.13% 41.30% 39.56% 38.35% 37.55% 40.52% 38.02% 37.27% 37.40% 44.15% 44.27%
Earnings before Interest and Taxes (EBIT)
1,865 1,497 1,665 1,991 2,075 1,827 2,200 2,224 2,400 1,517 1,823
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2,678 2,302 2,470 2,792 2,882 2,583 2,977 3,015 3,192 2,320 2,883
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4.83 5.03 4.57 4.96 4.09 4.69 4.66 4.55 4.16 3.41 3.07
Price to Tangible Book Value (P/TBV)
30.51 27.39 21.97 22.47 10.90 11.93 11.38 10.85 9.60 0.00 0.00
Price to Revenue (P/Rev)
4.65 4.84 4.42 4.79 4.65 5.41 5.46 5.29 4.89 3.93 3.37
Price to Earnings (P/E)
32.57 34.69 32.36 34.24 14.56 16.96 16.85 16.60 33.23 28.25 28.93
Dividend Yield
1.90% 1.85% 2.05% 1.90% 1.96% 1.70% 1.68% 1.74% 1.89% 2.35% 2.71%
Earnings Yield
3.07% 2.88% 3.09% 2.92% 6.87% 5.90% 5.93% 6.02% 3.01% 3.54% 3.46%
Enterprise Value to Invested Capital (EV/IC)
4.17 4.30 3.96 4.32 3.70 4.22 4.22 4.18 3.87 2.56 2.33
Enterprise Value to Revenue (EV/Rev)
4.82 5.03 4.58 4.95 4.78 5.54 5.59 5.40 4.97 4.51 3.94
Enterprise Value to EBITDA (EV/EBITDA)
19.02 20.18 18.65 19.91 19.21 21.88 21.46 20.66 18.74 17.70 16.08
Enterprise Value to EBIT (EV/EBIT)
27.93 29.81 27.59 29.06 27.76 31.06 29.78 28.42 25.49 24.41 23.04
Enterprise Value to NOPAT (EV/NOPAT)
34.73 37.03 33.74 35.81 15.39 17.93 18.12 17.86 35.53 34.26 34.58
Enterprise Value to Operating Cash Flow (EV/OCF)
26.61 28.37 23.63 23.37 23.45 26.23 26.67 25.95 23.05 21.51 18.52
Enterprise Value to Free Cash Flow (EV/FCFF)
68.77 66.11 41.14 43.34 38.38 50.76 70.44 59.77 63.67 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.38 0.37 0.37 0.37 0.29 0.27 0.26 0.25 0.25 0.65 0.63
Long-Term Debt to Equity
0.35 0.32 0.33 0.32 0.26 0.26 0.25 0.23 0.19 0.56 0.57
Financial Leverage
0.19 0.20 0.21 0.20 0.16 0.17 0.15 0.14 0.10 0.33 0.32
Leverage Ratio
1.95 1.92 1.90 1.88 1.78 1.75 1.74 1.74 1.67 1.89 1.88
Compound Leverage Factor
1.88 1.84 1.84 1.84 1.74 1.70 1.70 1.70 1.64 1.80 1.57
Debt to Total Capital
27.43% 27.20% 27.16% 27.23% 22.77% 21.25% 20.91% 20.16% 19.68% 39.25% 38.65%
Short-Term Debt to Total Capital
2.02% 3.75% 2.97% 3.92% 2.42% 0.81% 0.79% 2.09% 4.62% 5.08% 3.56%
Long-Term Debt to Total Capital
25.42% 23.45% 24.19% 23.32% 20.35% 20.44% 20.12% 18.06% 15.06% 34.17% 35.09%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.42% 0.43% 0.45% 0.42% 0.38% 0.41% 0.41% 0.48% 0.98% 0.74% 0.77%
Common Equity to Total Capital
72.15% 72.37% 72.39% 72.35% 76.85% 78.34% 78.68% 79.36% 79.35% 60.01% 60.58%
Debt to EBITDA
1.44 1.45 1.47 1.46 1.35 1.23 1.20 1.13 1.10 2.96 2.86
Net Debt to EBITDA
0.65 0.71 0.66 0.61 0.50 0.51 0.46 0.37 0.26 2.23 2.27
Long-Term Debt to EBITDA
1.34 1.25 1.31 1.25 1.21 1.19 1.15 1.01 0.84 2.58 2.59
Debt to NOPAT
2.64 2.67 2.67 2.63 1.08 1.01 1.01 0.98 2.08 5.73 6.15
Net Debt to NOPAT
1.19 1.30 1.20 1.10 0.40 0.42 0.39 0.32 0.50 4.32 4.88
Long-Term Debt to NOPAT
2.44 2.30 2.37 2.25 0.97 0.97 0.97 0.88 1.59 4.99 5.58
Altman Z-Score
4.75 5.00 4.75 4.97 5.05 5.81 5.83 5.80 5.37 3.01 2.83
Noncontrolling Interest Sharing Ratio
0.59% 0.60% 0.61% 0.57% 0.53% 0.55% 0.56% 0.59% 0.87% 0.88% 0.89%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.64 1.60 1.68 1.60 1.67 1.78 1.82 1.70 1.58 1.39 1.38
Quick Ratio
1.00 0.95 1.02 1.00 1.05 1.09 1.14 1.09 1.02 0.84 0.80
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-1,173 -1,225 357 587 874 -7,206 -8,181 -7,737 -1,048 -22,876 -20,662
Operating Cash Flow to CapEx
402.38% 257.54% 367.73% 486.51% 398.33% 292.77% 407.77% 561.90% 481.13% 329.57% 500.60%
Free Cash Flow to Firm to Interest Expense
-7.38 -8.69 2.55 4.14 6.43 -55.01 -67.61 -63.94 -8.73 -131.47 -58.87
Operating Cash Flow to Interest Expense
19.11 7.27 14.00 19.05 21.09 10.82 16.92 23.03 27.63 7.56 7.09
Operating Cash Flow Less CapEx to Interest Expense
14.36 4.45 10.19 15.13 15.79 7.12 12.77 18.93 21.88 5.26 5.67
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.54 0.55 0.56 0.56 0.54 0.55 0.55 0.55 0.53 0.47 0.48
Accounts Receivable Turnover
6.28 6.39 6.25 6.08 6.22 6.08 5.82 5.77 5.97 5.81 5.62
Inventory Turnover
2.82 2.68 2.66 2.72 2.93 2.78 2.75 2.86 3.05 2.90 2.83
Fixed Asset Turnover
4.15 4.16 4.14 4.09 4.03 4.03 3.99 3.96 3.94 3.87 3.85
Accounts Payable Turnover
4.04 4.34 4.37 4.58 4.41 4.46 4.50 4.74 4.58 4.44 4.44
Days Sales Outstanding (DSO)
58.16 57.14 58.37 60.00 58.69 60.05 62.77 63.23 61.15 62.82 64.92
Days Inventory Outstanding (DIO)
129.38 136.07 137.02 134.12 124.53 131.34 132.51 127.60 119.80 125.99 128.84
Days Payable Outstanding (DPO)
90.38 84.11 83.47 79.64 82.83 81.85 81.14 76.98 79.68 82.21 82.17
Cash Conversion Cycle (CCC)
97.16 109.09 111.93 114.47 100.39 109.54 114.13 113.84 101.27 106.60 111.59
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
46,383 47,119 47,177 47,263 54,197 55,587 57,056 56,551 56,940 79,463 78,749
Invested Capital Turnover
0.89 0.88 0.87 0.88 0.83 0.82 0.83 0.84 0.80 0.67 0.69
Increase / (Decrease) in Invested Capital
2,754 2,407 995 990 7,814 8,468 9,879 9,288 2,743 23,876 21,693
Enterprise Value (EV)
193,196 202,660 186,711 203,946 200,669 234,741 241,039 236,652 220,478 203,598 183,479
Market Capitalization
186,371 195,310 179,811 197,435 195,160 228,997 235,578 232,085 216,765 177,296 156,933
Book Value per Share
$22.24 $22.30 $22.60 $22.87 $27.48 $28.14 $29.06 $29.28 $29.98 $29.96 $29.34
Tangible Book Value per Share
$3.52 $4.10 $4.70 $5.05 $10.33 $11.07 $11.89 $12.29 $12.98 ($0.60) ($0.77)
Total Capital
53,506 53,629 54,314 55,007 62,026 62,306 64,266 64,205 65,700 86,748 84,370
Total Debt
14,679 14,586 14,754 14,979 14,125 13,242 13,437 12,941 12,929 34,047 32,608
Total Long-Term Debt
13,599 12,576 13,139 12,825 12,625 12,736 12,930 11,596 9,896 29,638 29,603
Net Debt
6,601 7,117 6,658 6,279 5,272 5,491 5,197 4,257 3,072 25,662 25,894
Capital Expenditures (CapEx)
755 398 533 556 720 484 502 496 689 399 497
Debt-free, Cash-free Net Working Capital (DFCFNWC)
2,630 3,714 3,755 3,266 3,032 3,811 4,254 3,869 3,594 4,245 4,105
Debt-free Net Working Capital (DFNWC)
9,909 10,365 10,974 11,054 10,999 10,655 11,536 11,602 12,533 11,540 9,708
Net Working Capital (NWC)
8,829 8,355 9,359 8,900 9,499 10,149 11,029 10,257 9,500 7,131 6,703
Net Nonoperating Expense (NNE)
-13 -43 50 -69 -541 -63 -81 -93 -81 -77 103
Net Nonoperating Obligations (NNO)
7,556 8,076 7,617 7,235 6,296 6,523 6,227 5,287 4,169 26,762 26,987
Total Depreciation and Amortization (D&A)
813 805 805 801 807 756 777 791 792 803 1,060
Debt-free, Cash-free Net Working Capital to Revenue
6.56% 9.21% 9.22% 7.92% 7.23% 9.00% 9.87% 8.82% 8.11% 9.41% 8.81%
Debt-free Net Working Capital to Revenue
24.71% 25.70% 26.95% 26.82% 26.22% 25.16% 26.76% 26.46% 28.27% 25.57% 20.84%
Net Working Capital to Revenue
22.01% 20.72% 22.98% 21.59% 22.64% 23.97% 25.58% 23.39% 21.43% 15.80% 14.39%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.92 $0.70 $0.74 $0.94 $5.29 $0.76 $1.02 $0.94 $1.01 $0.62 $0.53
Adjusted Weighted Average Basic Shares Outstanding
1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B
Adjusted Diluted Earnings per Share
$0.91 $0.70 $0.74 $0.94 $5.26 $0.76 $1.01 $0.94 $1.01 $0.61 $0.53
Adjusted Weighted Average Diluted Shares Outstanding
1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.74B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.74B 1.74B 1.74B 1.73B 1.73B 1.74B 1.74B 1.74B 1.74B 1.74B 1.73B
Normalized Net Operating Profit after Tax (NOPAT)
1,581 1,182 1,352 1,577 1,338 1,262 1,698 1,551 1,695 1,000 1,031
Normalized NOPAT Margin
15.43% 11.87% 13.03% 14.83% 12.19% 12.18% 15.24% 13.64% 14.80% 8.95% 8.19%
Pre Tax Income Margin
17.53% 14.41% 15.49% 18.24% 18.50% 17.17% 19.30% 19.17% 20.58% 12.98% 12.10%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
11.73 10.62 11.89 14.02 15.26 13.95 18.18 18.38 20.00 8.72 5.19
NOPAT to Interest Expense
9.94 8.39 9.66 11.11 63.88 9.63 14.03 12.82 14.13 5.75 2.94
EBIT Less CapEx to Interest Expense
6.98 7.79 8.09 10.11 9.96 10.25 14.03 14.28 14.26 6.43 3.78
NOPAT Less CapEx to Interest Expense
5.19 5.56 5.85 7.19 58.59 5.94 9.88 8.72 8.39 3.45 1.52
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
62.14% 64.35% 66.47% 65.30% 28.62% 28.92% 28.42% 28.93% 63.09% 66.73% 78.54%
Augmented Payout Ratio
83.58% 80.57% 75.29% 86.79% 38.29% 38.91% 38.09% 35.42% 76.78% 79.37% 112.31%

Financials Breakdown Chart

Key Financial Trends

Abbott Laboratories (NYSE: ABT) posted a mixed start to 2026, with earnings holding up but cash flow and balance sheet leverage looking less comfortable than in prior periods. Over the last four years, Abbott has generally shown resilient revenue, solid profitability, and strong dividend support, but the latest quarter also reflects a major acquisition-driven jump in debt and a sharp drop in cash.

  • Revenue remains stable at a large scale. Q1 2026 revenue was $11.16 billion, essentially flat versus Q4 2025 and above Q1 2025’s $10.36 billion, showing Abbott can keep top-line performance steady even in a slower growth environment.
  • Profitability is still healthy. Q1 2026 net income was $1.08 billion, with diluted EPS of $0.61. That is down from the stronger Q4 2025, but still indicates consistent earnings power.
  • Operating cash flow remains positive. Abbott generated $1.32 billion in operating cash flow in Q1 2026, which supports ongoing dividends, buybacks, and reinvestment.
  • The company continues to produce strong annual cash generation. In 2024, Abbott generated $2.87 billion in Q4 operating cash flow, and across 2024–2025 its quarterly operating cash flow has generally remained robust.
  • Gross margins appear relatively durable. Q1 2026 gross profit was $6.27 billion on $11.16 billion of revenue, suggesting Abbott’s core product economics remain strong.
  • Research and development spending is steady. Q1 2026 R&D expense was $767 million, in line with recent quarters, which suggests continued investment in the pipeline but not an aggressive step-up.
  • Dividend coverage merits attention. Q1 2026 cash dividends per share were $0.63, while diluted EPS was $0.61. That does not necessarily imply a problem, but it suggests the dividend is being maintained at a level that can outpace quarterly earnings in some periods.
  • Working capital needs are still meaningful. Accounts receivable, inventories, and prepaid expenses remain large components of current assets, which is normal for a global healthcare company but ties up cash.
  • Cash fell sharply after a large acquisition. Q1 2026 investing cash flow was a massive negative $20.32 billion, driven by $19.80 billion of acquisitions, and cash & equivalents fell to $6.80 billion from $7.62 billion at year-end 2024.
  • Leverage increased materially. Long-term debt rose to $29.64 billion in Q1 2026 from $12.63 billion at Q4 2024 and $11.60 billion at Q3 2025, which is a significant balance sheet shift.

Looking at the broader trend, Abbott’s revenue has been remarkably steady over the last several years, generally ranging around the $10 billion to $11.5 billion quarterly level. Earnings also improved materially versus 2023, when quarterly EPS was often in the $0.70 to $0.90 range, and then strengthened further in 2024 and 2025, with several quarters above $1.00 per share.

The main issue for investors is not the income statement; it is the capital allocation and balance sheet impact of the latest quarter. Abbott moved from a relatively conservative debt profile in late 2024 and 2025 to a much more leveraged position in Q1 2026. At the same time, the acquisition consumed a huge amount of cash, leaving far less flexibility than before.

Bottom line: Abbott still looks like a high-quality, cash-generative healthcare company with dependable earnings and dividend support, but the Q1 2026 acquisition materially raised financial risk. Retail investors should watch whether the new debt level is quickly offset by improved earnings, operating cash flow, and post-deal synergies.

08/05/26 02:50 AM ETAI Generated. May Contain Errors.

Abbott Laboratories Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Abbott Laboratories' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Abbott Laboratories' net income appears to be on an upward trend, with a most recent value of $6.52 billion in 2025, rising from $4.42 billion in 2015. The previous period was $13.40 billion in 2024. See where experts think Abbott Laboratories is headed by visiting Abbott Laboratories' forecast page.

Abbott Laboratories' total operating income in 2025 was $8.05 billion, based on the following breakdown:
  • Total Gross Profit: $25.01 billion
  • Total Operating Expenses: $16.96 billion

Over the last 10 years, Abbott Laboratories' total revenue changed from $20.41 billion in 2015 to $44.33 billion in 2025, a change of 117.2%.

Abbott Laboratories' total liabilities were at $33.94 billion at the end of 2025, a 1.3% increase from 2024, and a 70.4% increase since 2015.

In the past 10 years, Abbott Laboratories' cash and equivalents has ranged from $3.84 billion in 2018 to $18.62 billion in 2016, and is currently $8.52 billion as of their latest financial filing in 2025.

Over the last 10 years, Abbott Laboratories' book value per share changed from 14.18 in 2015 to 29.98 in 2025, a change of 111.4%.



Financial statements for NYSE:ABT last updated on 7/28/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners